UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment

Journal of clinical pharmacology, 2016-12, Vol.56 (12), p.1484-1499

2016

Volltextzugriff (PDF)

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

Molecular cancer therapeutics, 2009-09, Vol.8 (9), p.2496-2508

2009

Volltextzugriff (PDF)

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance

Cancer biology & therapy, 2018-10, Vol.19 (10), p.869-870

2018

Volltextzugriff (PDF)

Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer

Clinical cancer research, 2008-06, Vol.14 (11), p.3312-3318

2008

Volltextzugriff (PDF)

ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel

Clinical cancer research, 2008-07, Vol.14 (14), p.4543-4549

2008

Volltextzugriff (PDF)

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

Journal of experimental & clinical cancer research, 2010-07, Vol.29 (1), p.95-95, Article 95

2010

Volltextzugriff (PDF)

Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA) n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?

International journal of molecular sciences, 2020-01, Vol.21 (3), p.896

2020

Volltextzugriff (PDF)

Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention

Molecular cancer research, 2006-03, Vol.4 (3), p.135-150

2006

Volltextzugriff (PDF)

Disclosing a Diagnosis of Cancer: Where and How Does It Occur?

Journal of clinical oncology, 2010-08, Vol.28 (22), p.3630-3635

2010

Volltextzugriff (PDF)

Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma

Clinical cancer research, 2009-02, Vol.15 (4), p.1496-1503

2009

Volltextzugriff (PDF)

Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32

Drug metabolism letters, 2018, Vol.12 (2), p.153-153

2018

Volltextzugriff (PDF)

Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel

Clinical cancer research, 2006-08, Vol.12 (15), p.4636-4640

2006

Volltextzugriff (PDF)

Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models

Molecular cancer therapeutics, 2021-05, Vol.20 (5), p.915-924

2021

Volltextzugriff (PDF)

Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN-38

Journal of clinical pharmacology, 2004-08, Vol.44 (8), p.854-860

2004

Volltextzugriff (PDF)

Genome‐wide Association Study Identified Chromosome 8 Locus Associated with Medication‐Related Osteonecrosis of the Jaw

Clinical pharmacology and therapeutics, 2021-12, Vol.110 (6), p.1558-1569

2021

Volltextzugriff (PDF)

Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer

Molecular cancer, 2014-04, Vol.13 (1), p.91-91, Article 91

2014

Volltextzugriff (PDF)

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

Cancer biology & therapy, 2020-09, Vol.21 (9), p.782-784

2020

Volltextzugriff (PDF)

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells

Molecular pharmacology, 2015-06, Vol.87 (6), p.1006-1012

2015

Volltextzugriff (PDF)

Mapping a path for cancer precision medicine

The lancet oncology, 2017-11, Vol.18 (11), p.1444-1444

2017

Volltextzugriff (PDF)

Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

Clinical cancer research, 2005-10, Vol.11 (20), p.7398-7404

2005

Volltextzugriff (PDF)

BET bromodomain inhibitors-A novel epigenetic approach in castration-resistant prostate cancer

Cancer biology & therapy, 2014-01, Vol.15 (12), p.1583-1585

2014

Volltextzugriff (PDF)

Genetic variant associated with aggressive not indolent prostate cancer

Cancer biology & therapy, 2010-06, Vol.9 (12), p.957-958

2010

Volltextzugriff (PDF)

PARP inhibitors on the move in prostate cancer: spotlight on Niraparib & update on PARP inhibitor combination trials

American journal of clinical and experimental urology, 2022-01, Vol.10 (4), p.252-257

2022

Volltextzugriff (PDF)

VEGF inhibition and metastasis: Possible implications for antiangiogenic therapy

Cancer biology & therapy, 2009-07, Vol.8 (13), p.1212-1213

2009

Volltextzugriff (PDF)

shRNA technology: Investigating Ras-dependent cancer

Cancer biology & therapy, 2009-10, Vol.8 (19), p.1798-1799

2009

Volltextzugriff (PDF)

1 – 25 von 353

Suche als RSS-Feed

Aktive Filter

ThemaProstate Cancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(324)
Mit Volltextzugriff
(289)

Publikationsform

Sprache

Englisch
(351)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance

Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer

ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA) n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?

Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention

Disclosing a Diagnosis of Cancer: Where and How Does It Occur?

Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma

Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32

Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel

Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models

Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN-38

Genome‐wide Association Study Identified Chromosome 8 Locus Associated with Medication‐Related Osteonecrosis of the Jaw

Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells

Mapping a path for cancer precision medicine

Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

BET bromodomain inhibitors-A novel epigenetic approach in castration-resistant prostate cancer

Genetic variant associated with aggressive not indolent prostate cancer

PARP inhibitors on the move in prostate cancer: spotlight on Niraparib & update on PARP inhibitor combination trials

VEGF inhibition and metastasis: Possible implications for antiangiogenic therapy

shRNA technology: Investigating Ras-dependent cancer

Aktive Filter

Suchergebnisse filtern